EC approves Filspari for the treatment of IgA nephropathy

San Diego, USA-based Travere Therapeutics (Nasdaq: TVTX) and CSL Vifor today announced that the European Commission has granted conditional marketing authorization (CMA) for Filspari (sparsentan) for the treatment of adults with primary IgA nephropathy (IgAN) with a urine protein excretion ≥1.0 g/day (or urine protein-to-creatinine ratio ≥0.75 g/g).

Not withstanding the positive development, Travere’s shares were down more than 4% at $5.50 by late-morning trading. Filspari gained accelerated US regulatory approval more than a year ago.

The CMA is granted for all member states of the European Union, as well as in Iceland, Liechtenstein and Norway.